Telomerase reverse transcriptase (TERT) promoter mutation is a rare event in ovarian clear cell carcinomas in the Japanese population

Background: Telomerase reverse transcriptase (TERT) plays an important role in cancer cells. Recently, mutations in the promoter of the TERT gene were identified in several types of cancers, and have also been reported as indicators of poor outcome in some of these patients. The majority of reported mutations were located at two hotspots, -124C>T and -146C>T. The aim of this study was to examine the incidence of TERT promoter mutations in ovarian clear cell carcinomas (OCCCs) in the Japanese population. Materials and Methods: The authors screened for TERT promoter mutations (focusing on the two hotspots) in 40 patients with OCCCs: 11 patients with endometrioid carcinoma, and 10 patients with high-grade serous carcinoma. They further measured the effect of TERT promoter mutations in an OCCC cell line (ES-2) using the luciferase reporter assay. Results: The incidence of hotspot mutations was 2.5% (1/40) in the patients with OCCCs, but was 0% (0/11 and 0/10) in patients with endometrioid carcinoma and high-grade serous carcinoma. The luciferase assay confirmed that the identified hotspot mutation is a gain-of-function mutations in OCCC cells. Conclusion: TERT promoter mutations increased the activity of OCCC cells. However, the frequency of these mutations in OCCCs appears to be very rare in the Japanese population. The present data indicate that TERT promoter mutations do not play an important role in OCCCs in the Japanese population.

Ovarian clear cell carcinoma; Telomerase reverse transcriptase (TERT) promoter

[1] Sugiyama T., Kamura T., Kigawa J., Terakawa N., Kikuchi Y., Kita T., et al.: “Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy”. Cancer, 2000, 88, 2584.

[2] Reed E., Yu J.J., Davies A., Gannon J., Armentrout S.L.: “Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer”. Clin. Cancer Res., 2003, 9, 5299.

[3] Huang F.W., Hodis E., Xu M.J., Kryukov G.V., Chin L., Garraway L.A.: “Highly recurrent TERT promoter mutations in human melanoma”. Science, 2013, 339, 957.

[4] Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., et al.: “Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease”. J. Clin. Endocrinol. Metab., 2013, 98, E1562.

[5] Simon M., Hosen I., Gousias K., Rachakonda S., Heidenreich B., Gessi M., et al.: “TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas”. Neuro. Oncol., 2015, 17, 45.

[6] Melo M., da Rocha A.G., Vinagre J., Batista R., Peixoto J., Tavares C., et al.: “TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas”. J. Clin. Endocrinol. Metab., 2014, 99, E754.

[7] Allsopp R.C., Vaziri H., Patterson C., Goldstein S., Younglai E.V., Futcher A.B., et al.: “Telomere length predicts replicative capacity of human fibroblasts”. Proc. Natl. Acad. Sci. U. S. A., 1992, 89, 10114.

[8] Hayflick L., Morrhead P.S.: “The serial cultivation of human diploid cell strains”. Exp. Cell Res., 1961, 25, 585.

[9] Greider C.W., Blackburn E.H: “A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis”. Nature, 1989, 337, 331.

[10] Takakura M., Kyo S., Kanaya T., Hirano H., Takeda J., Yutsudo M., Inoue M.: “Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells”. Cancer Res., 1999, 59, 551.

[11] Cong YS, Wen J, and Bacchetti S, “The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter”. Hum. Mol. Genet., 1999, 8, 137.

[12] Bell R.J., Rube H.T., Kreig A., Mancini A., Fouse S.D., Nagarajan R.P., et al.: “Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer”. Science, 2015, 348, 1036.

[13] Wu R.C., Ayhan A., Maeda D., Kim K.R., Clarke B.A., Shaw P., et al.: “Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy”. J. Pathol., 2014, 232, 473.

[14] Kennedy A.W., Biscotti C.V., Hart W.R., Webster K.D.: “Ovarian clear cell adenocarcinoma”. Gynecol. Oncol., 1989, 32, 342.

[15] Sangi-Haghpeykar H., Poindexter A.N. 3rd: “Epidemiology of endometriosis among parous women”. Obstet. Gynecol., 1995, 85, 983.

[16] Hickey M., Ballard K., Farquhar C.: “Endometriosis”. BMJ, 2014, 348, g1752.

[17] McGuire V., Jesser C.A., Whittemore A.S.: “Survival among U.S. women with invasive epithelial ovarian cancer”. Gynecol. Oncol., 2002, 84, 399.

[18] Okamoto A., Sehouli J., Yanaihara N., Hirata Y., Braicu I., Kim B.G., et al.: “Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma”. PLoS One, 2015, 10, e0116977.

[19] Bullock M., Ren Y., O’Neill C., Gill A., Aniss A., Sywak M., et al.: “TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas”. Clin. Endocrinol. (Oxf.), 2016, 85, 283.

[20] Park J.I., Venteicher A.S., Hong J.Y., Choi J., Jun S., Shkreli M., et al.: “Telomerase modulates Wnt signalling by association with target gene chromatin”. Nature, 2009, 460, 66.

[21] Zhang S., Li Y., Wu Y., Shi K., Bing L., Hao J.: “Wnt/beta-catenin signaling pathway upregulates c-Myc expression to promote cell proliferation of P19 teratocarcinoma cells”. Anat. Rec. (Hoboken), 2012, 295, 2104.